ADC Therapeutics SA Net Income 2019-2023 | ADCT
ADC Therapeutics SA net income from 2019 to 2023. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
ADC Therapeutics SA Annual Net Income
(Millions of US $) |
| 2022 |
$-156 |
| 2021 |
$-230 |
| 2020 |
$-246 |
| 2019 |
$-116 |
| 2018 |
$-123 |
ADC Therapeutics SA Quarterly Net Income
(Millions of US $) |
| 2023-03-31 |
$-59 |
| 2022-12-31 |
$-24 |
| 2022-09-30 |
$-51 |
| 2022-06-30 |
$-64 |
| 2022-03-31 |
$-17 |
| 2021-12-31 |
$-34 |
| 2021-09-30 |
$-72 |
| 2021-06-30 |
$-73 |
| 2021-03-31 |
$-52 |
| 2020-12-31 |
$-56 |
| 2020-09-30 |
$-20 |
| 2020-06-30 |
$-127 |
| 2020-03-31 |
$-43 |
| 2019-12-31 |
|
| 2019-09-30 |
$-31 |
| 2019-06-30 |
$-23 |
| 2018-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.191B |
$0.210B |
|
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
|
